Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany
Open Access
- 26 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (11) , 2122-2134
Abstract
Objectives. To estimate the cost-effectiveness of etanercept (ETN) plus usual care (including NSAIDs) compared with usual care alone (including NSAIDs) in patients with severe AS in Germany. Methods. A mathematical model previously applied to the UK was adapted using resource use and cost data (for 2007) from the national database of the German Collaborative Arthritis Centres. Social health insurance (SHI) and societal perspectives were analysed. Assumptions on initial response and changes in health-related quality of life were based on Phase III randomized controlled trials. Initial treatment response according to British Society for Rheumatology guidelines were assumed as a conservative estimate in the German context. Long-term disease progression was based on the available literature. Incremental cost–effectiveness ratios (ICERs) were expressed as euros/quality-adjusted life year (QALY), for a cohort of 1000 patients over 25 years. Sensitivity analyses explored uncertainty in results. Results. In the base case, ETN plus usual care (including NSAIDs) yielded 1475 more QALYs at an additional cost of €80 827 668 (SHI) or €32 657 590 (societal) leading to an ICER of €54 815/QALY and €22 147/QALY, respectively. Over a shorter time horizon of 10 years, the ICERs were €59 006 and €29 815 for SHI and societal viewpoints, respectively. Assumptions having the largest impact on results included withdrawal rates from ETN, quality of life, disease costs and initial response. Conclusions. Cost-effectiveness for ETN in patients with severe AS in Germany differs according to the cost perspective. Study estimates were higher than in the UK but comparable with reported cost-effectiveness of anti-TNF treatments in patients with RA in Germany.Keywords
This publication has 36 references indexed in Scilit:
- Using UtilitiesThe Journal of Rheumatology, 2010
- Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failureThe European Journal of Health Economics, 2009
- The OMERACT Initiative. Towards a Reference Approach to Derive QALY for Economic Evaluations in RheumatologyThe Journal of Rheumatology, 2009
- Ten arguments for a societal perspective in the economic evaluation of medical innovationsThe European Journal of Health Economics, 2009
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force ReportValue in Health, 2009
- The cost‐effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice dataScandinavian Journal of Rheumatology, 2008
- Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidanceRheumatology, 2007
- Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between CountriesPharmacoEconomics, 2004